Drug intelligence / Profile preview

omega-3 enriched olive oil

Development stage: Unknown
Lead developer: Nutra Omega Biotecnología Oleica
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Omega-3 enriched olive oil is a functional food composed of 68% extra virgin olive oil and 22% fish oil concentrate, rich in docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Developed by NUTRA OMEGA BIOTECNOLOGÍA OLEICA SL in collaboration with the Food Technology Research Group of the Universidad Autónoma de Madrid, it is being investigated for its potential benefits in subjects with grade II overweight/obesity and metabolic syndrome. It aims to modulate inflammatory response, oxidative stress, satiety, and body composition, and has been shown to improve the lipid composition of red blood cell membranes.

Other names: producto experimental

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on omega-3 enriched olive oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-3 enriched olive oil.

Explore the full profile